Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 61

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 61
---
/or pharmaceuticals, which would make it difficult for us to stop
a third party from infringing any of our intellectual property rights. Moreover, attempting to enforce our patent rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business.

 36 

Our products, drug candidates and compounded
formulations and technologies could potentially conflict with the rights of others.

The preparation or sale of our
products, drug candidates and compounded formulations and use of our technologies may infringe on the patent or other intellectual property
rights of others. If our products infringe or conflict with the patent or other intellectual property rights of others, third parties
could bring legal actions against us claiming damages and seeking to enjoin our manufacturing and marketing of our affected products.
Patent litigation is costly and time consuming and may divert management’s attention and our resources. We may not have sufficient
resources to bring any actions to a successful conclusion. If we are not successful in defending against these legal actions should they
arise, we may be subject to monetary liability or be forced to alter our products, cease some or all of our operations relating to the
affected products, or seek to obtain a license in order to continue manufacturing and marketing the affected products, which may not
be available on acceptable terms or at all.

We are dependent on our Chief Executive Officer,
Mark L. Baum and Chief Financial Officer, Andrew R. Boll, for the continued growth and development of our Company.

Our Chief Executive Officer,
Mark L. Baum and our Chief Financial Officer, Andrew R. Boll, have played a primary role in the founding of our business along with creating
and developing our current business model. We are highly dependent on these executives for the implementation of our business plan and
the future development of our assets and our business, and the loss of their services and leadership could materially adversely impact
our Company.

If we are unable to attract and retain key
personnel and consultants, we may be unable to maintain or expand our business.

We have been focusing on building
our management, pharmacy, research and development, sales and marketing and other personnel to pursue our current business model. To
achieve our planned growth, we may have significant difficulty attracting and retaining necessary employees. Because of the specialized
nature of our business, our ability to develop products and to compete will remain highly dependent upon our ability to attract and retain
qualified pharmacy, scientific, technical and commercial employees and consultants. There is intense competition to hire qualified personnel